Sionna Therapeutics, Inc.
SIONNasdaqCIK 2036042HealthcareFiscal year ends Dec 31
Reports and events: 33 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-2118:57 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-26-000239 |
| 2026-09-1416:10 ET | 8-K | 2.05 Exit or disposal costs; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-390577 |
| 2026-08-1007:15 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-341230 |
| 2026-08-0607:19 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-053839 |
| 2026-08-0607:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-053832 |
| 2026-06-1816:05 ET | 8-K | 5.07 Shareholder vote results | 0001628280-26-044263 |
| 2026-05-1207:17 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-033876 |
| 2026-05-1207:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-033870 |
| 2026-04-2716:04 ET | DEF 14A | Proxy statementPeriod 2026-06-17 | 0001628280-26-027489 |
| 2026-04-2018:46 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0000947871-26-000456 |
| 2026-03-0207:19 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-012996 |
| 2026-03-0207:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-012993 |
| 2025-11-0716:59 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001346824-25-000045 |
| 2025-11-0507:28 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001628280-25-049251 |
| 2025-11-0507:14 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-25-049246 |
| 2025-10-2021:40 ET | SCHEDULE 13D/A | Ownership report, active investor, amended | 0001708269-25-000004 |
| 2025-08-1107:21 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0002036042-25-000047 |
| 2025-08-1107:13 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002036042-25-000044 |
| 2025-06-1316:09 ET | 8-K | 5.07 Shareholder vote results | 0002036042-25-000018 |
| 2025-06-0407:13 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-25-134462 |
| 2025-05-1207:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0002036042-25-000016 |
| 2025-05-1207:12 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0002036042-25-000014 |
| 2025-04-2907:28 ET | DEF 14A | Proxy statementPeriod 2025-06-12 | 0001193125-25-101830 |
| 2025-03-2007:27 ET | 10-K | Annual reportPeriod 2024-12-31 | 0002036042-25-000005 |
| 2025-03-2007:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-25-058306 |
| 2025-02-1820:56 ET | SCHEDULE 13D | Ownership report, active investor | 0001839882-25-009559 |
| 2025-02-1816:59 ET | SCHEDULE 13D | Ownership report, active investor | 0001415889-25-004453 |
| 2025-02-1816:25 ET | SCHEDULE 13D | Ownership report, active investor | 0001415889-25-004419 |
| 2025-02-1816:22 ET | SCHEDULE 13D | Ownership report, active investor | 0001415889-25-004410 |
| 2025-02-1316:47 ET | SCHEDULE 13D | Ownership report, active investor | 0000947871-25-000138 |
| 2025-02-1016:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-25-023570 |
| 2025-02-0306:06 ET | S-1/A | Registration statement, amended | 0001193125-25-018825 |
| 2025-01-1717:00 ET | S-1 | Registration statement | 0001193125-25-008474 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.